SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is driving the discussion, with traders citing reported losses, concerns about further share dilution and questions about Truth Socials engagement as reasons for skepticism. Political backlash and midterm worries add to the bearish tone, while some holders still view the decline as a buying opportunity.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs continued slide to fresh lows is drawing attention, with traders citing analyst target cuts and concerns about weak housing and roofing demand, high rates, and the debt and dilution tied to its acquisition-led expansion. The conversation is sharply divided between frustrated holders calling for clearer communication and evidence of integration progress, and bullish investors treating the selloff as an opportunity to accumulate ahead of earnings.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp advance is being attributed mainly to Morgan Stanley naming it a top pick, citing expected AWS growth and AI opportunities. Traders are broadly bullish on the rebound, though some question whether the upgrade-driven move will hold ahead of earnings.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff has focused attention on its debt burden, rising financing costs and whether AI demand can translate into cash flow; traders are divided over whether these risks threaten the business or are being overstated. Goldman Sachs Buy upgrade after the decline prompted hopes for a rebound, but skepticism about the upgrade and fading gains remained prominent.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met both co-primary and all secondary endpoints in the Phase 3 APOLLO trial for EPP, strengthening the case for an NDA resubmission after the FDAs earlier rejection. Traders are broadly bullish on the data and speculate about a short squeeze, while others point to profit-taking, resistance, and concerns about dizziness or a possible sell-the-news reaction.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and underperformance relative to Bitcoin dominate discussion, with traders blaming weak management and the lack of signed AI/data-center tenant deals as the company pursues a pivot beyond mining. Bearish frustration over the falling shares and perceived short pressure competes with dip-buying and hopes that a lease announcement or Bitcoin strength could improve sentiment.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular shares are under pressure as EyePoints failed wet-AMD trial has raised concerns among traders about the TKI approach, while the departure of Oculars chief strategy officer and uncertainty around the AXPAXLI NDA add to unease. Some traders see the setback as a warning about shared clinical risks; others argue AXPAXLIs positive SOL-1 results and FDA-aligned filing path set it apart.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunruns steep slide is driving debate over whether high financing costs, policy headwinds and balance-sheet risks could threaten the company, with some traders comparing it to failed solar peers. Bulls counter that its battery fleet, virtual power plants and emerging AI data-center power opportunities could support a broader energy-infrastructure business, though many remain skeptical after repeated declines.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention after traders cited strong earnings and year-over-year revenue growth, alongside optimism that AI data-center demand for indium-phosphide substrates can support further growth. The reaction is sharply divided: bulls focus on the AI-optics opportunity, while bears point to the stocks steep run-up, rich valuation, China-related risks, and volatile pullbacks.

Annaly Capital Management, Inc. engages in the investment and financing of residential and commercial assets. It operates through the following segments: Agency, Residential Credit, Mortgage Servicing Rights (MSR), and Corporate and Other. The Agency segment invests in agency mortgage-backed securities. The Residential Credit segment is involved in non-agency residential mortgage assets within securitized products and whole loan markets. The MSR segment provides the right to service residential mortgage loans in exchange for a portion of the interest payments made on the loans. The company was founded by Michael A. J. Farrell and Wellington Jamie Denahan-Norris on November 25, 1996 and is headquartered in New York, NY.

Annaly Capital Management Inc

Annaly is drawing attention as mortgage REITs sell off and shares hit a reported 52-week low; traders point to rate concerns and mortgage-bond repricing. Some holders are buying the dip for the high dividend, while others worry about book value, leverage and further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LB Pharmaceuticals Appoints Susan Kozauer As CMO

(RTTNews) - LB Pharmaceuticals Inc. (LBRX), a neuromedicines company, on Tuesday appointed Susan Kozauer as Chief Medical Officer...

LB Pharmaceuticals Names Joseph Miller CFO

(RTTNews) - On Thursday, LB Pharmaceuticals Inc. (LBRX) announced the appointment of Joseph Miller as Chief Financial Officer. LB Pharma is a neuromedicines company dedicated to developing and commercializing therapies that address the multiple dimensions of underserved brain dis...

All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy

LB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LB Pharmaceuticals (NASDAQ:LBRX) Raised to "Strong-Buy" at HC Wainwright

HC Wainwright upgraded shares of LB Pharmaceuticals to a "strong-buy" rating in a research note on Monday...

LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week High  - What's Next?

LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 52-Week High - Here's Why...

LB Pharmaceuticals (NASDAQ:LBRX) Trading 5.6% Higher - Time to Buy?

LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 5.6% - Time to Buy...

LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High - Time to Buy?

LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High - Should You Buy...

LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham

LB Pharmaceuticals (NASDAQ:LBRX) is seeking to build a "fully integrated company focused on CNS-related diseases," Chief Executive Officer Heather Turner said during a presentation at a Needham conference hosted by biotech analyst Ami Fadia.

Turner said the company's lead program, LB-102, is a late...

LB Pharmaceuticals (NASDAQ:LBRX) Shares Down 4.5% - Should You Sell?

LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 4.5% - Here's Why...

LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 1-Year High - Should You Buy?

LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 12-Month High - Here's Why...

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.

LB Pharmaceuticals Inc

Bullish Sentiment

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$39.37
Prev Close	$36.74
Open	$36.98
Dividend Yield	0.00%
50-Day Moving Average	$42.81
Beta	0.83
Avg. Volume	345,636.91
PE Ratio	-12.33

52-Week High	$50.16
52-Week Low	$14.32
Market Capitalization	$1.19B
EPS (Annual)	-$0.9963
Price to Book	3.17
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

LBRX Fundamentals